Protocol: CDISCPILOT01                                                                  Page  1 of 1 
Population: Safety 
Table 14-4.01 
Summary of Planned Exposure to Study Drug, as of End of Study 
 
 
[1] Includes completers and early terminators. 
[2] End of Study refers to week 26/Early Termination. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl12.sas                    21:02 Monday, June 26, 2006 
 
Completers at Week 24 
Safety Population [1] 
 
________________________________ ________________________________
 
Placebo 
(N=60) 
Xanomeline
Low Dose
(N=28) 
Xanomeline
High Dose
(N=30) 
Placebo 
(N=86) 
Xanomeline
Low Dose
(N=84) 
Xanomeline
High Dose
(N=84) 
 
Average daily dose (mg)            n 
   60 
   28 
   30 
   86 
   84 
   84 
 
mean     0.0 
   54.0 
   77.0 
    0.0 
   54.0 
   71.6 
 
std 
    0.00 
    0.00 
    0.58 
    0.00 
    0.00 
    8.11 
 
median    0.0 
   54.0 
   76.9 
    0.0 
   54.0 
   75.1 
 
min 
    0.0 
   54.0 
   76.1 
    0.0 
   54.0 
   54.0 
 
max 
    0.0 
   54.0 
   78.6 
    0.0 
   54.0 
   78.6 
 
Cumulative dose at end of study [2] n 
   60 
   28 
   30 
   86 
   84 
   84 
 
mean     0.0 
 9918.6 
14089.5 
    0.0 
 5347.3 
 7551.0 
 
std 
    0.00 
  603.84 
  481.01 
    0.00 
 3680.35 
 5531.04 
 
median    0.0 
 9936.0 
14080.5 
    0.0 
 4455.0 
 5778.0 
 
min 
    0.0 
 7884.0 
12960.0 
    0.0 
  108.0 
   54.0 
 
max 
    0.0 
11448.0 
15417.0 
    0.0 
11448.0 
15417.0 
 
